Guenther Boden, MD, has worked in the field of diabetes as a clinician and investigator for 40 over years. He began as Director of the Diabetes Outpatient Clinic at Temple University Hospital in Philadelphia in 1975 and in 1978 was named Chief of the Section of Diabetes. After 11 years, Dr. Boden became Chief of the Division of Endocrinology/Diabetes/Metabolism and Program Director of the General Clinical Research Center at Temple University School of Medicine.
During this time, his laboratory, which has been supported uninterruptedly by the National institutes of Health since 1973, made several seminal observations. Dr. Boden was the first to demonstrate that elevated plasma FFA levels produce peripheral insulin resistance (Journal of Clinical Investigation,1991, 1994 and 1995) and that lowering of chronically elevated plasma FFAs in obese, non-diabetic and diabetic patients improved insulin sensitivity (Diabetes1999). These results have since been widely confirmed and suggested that FFAs can account for up to 50 percent of insulin resistance in obese patients with type 2 diabetes.